SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Alexander Drilon(Memorial Sloan Kettering Cancer Center), S. Michael Rothenberg(Boulder Language Technologies (United States))
Cited by 65
Related Papers
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
|Nature Communications|2022|110